» Articles » PMID: 15801031

Employment Across Chronic Inflammatory Rheumatic Diseases and Comparison with the General Population

Overview
Journal J Rheumatol
Specialty Rheumatology
Date 2005 Apr 1
PMID 15801031
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To compare labor force participation across chronic inflammatory rheumatic diseases in order to assess the influence of the disease, disease duration, sex, education, and labor market conditions on employment.

Methods: Data from the German rheumatological database on outpatients of working age (20-59 yrs) between 1993 and 2001 were analyzed. The patients had rheumatoid arthritis (RA; n = 26,071), ankylosing spondylitis (AS; n = 5564), psoriatic arthritis (PsA; n = 6041), systemic lupus erythematosus (SLE; n = 4603), systemic sclerosis (SSc; n = 802), or Wegener's granulomatosis (WG; n = 385). Using population data, standardized employment ratios (SER) and part-time employment ratios of observed versus expected cases with 95% CI were calculated by means of indirect standardization for age and year of documentation.

Results: Across all diseases the overall employment rates were significantly lower than in the general population. Significant differences in SER were found between the diseases. The lowest SER of 0.76 to 0.81 (1.0 = population) were found in patients with RA, SLE, SSc, and WG. Higher SER were seen in AS (0.94) and PsA (0.92). In patients with a disease duration > 10 years the relative risk of being employed compared to RA, was 1.42 for AS, 1.26 for PsA, and 1.15, 1.03, 0.62 for PsA, SLE, SSc and WG, respectively. Comparing areas with low and high unemployment rates, a highly significant influence of labor market conditions on the SER was observed. The SER were significantly lower in patients with < 10 years of school education.

Conclusion: Differences between employment rates in the population and the rates for the diseases under study are smaller than assumed by most clinical studies, especially in AS and PsA. However, these differences increase with longer disease duration. Specific measures to prevent patients from losing their job are needed, especially in areas with overall high unemployment.

Citing Articles

Trends in work participation among patients with inflammatory rheumatic musculoskeletal diseases (iRMDs): Data from the German National Database (2010-2022).

Veltri C, Albrecht K, Kiltz U, Meyer-Olson D, Spathling S, Strangfeld A RMD Open. 2025; 11(1).

PMID: 39863303 PMC: 11792565. DOI: 10.1136/rmdopen-2024-004980.


Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy.

Williams J, Hum R, Rogers K, Maglio C, Alam U, Zhao S Ther Adv Musculoskelet Dis. 2024; 16:1759720X241271886.

PMID: 39161788 PMC: 11331474. DOI: 10.1177/1759720X241271886.


The HAVEN study-hydroxychloroquine in ANCA vasculitis evaluation-a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan.

Learoyd A, Arnold L, Reid F, Beckley-Hoelscher N, Casian A, Sangle S Trials. 2023; 24(1):261.

PMID: 37024906 PMC: 10077754. DOI: 10.1186/s13063-023-07108-3.


Cost-effectiveness of cognitive behavioural and personalized exercise interventions for reducing fatigue in inflammatory rheumatic diseases.

Chong H, McNamee P, Bachmair E, Martin K, Aucott L, Dhaun N Rheumatology (Oxford). 2023; 62(12):3819-3827.

PMID: 37018151 PMC: 10691924. DOI: 10.1093/rheumatology/kead157.


Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis.

Tillett W, Coates L, Kiri S, Taieb V, Willems D, Mease P Ther Adv Musculoskelet Dis. 2022; 14:1759720X221140846.

PMID: 36533099 PMC: 9755548. DOI: 10.1177/1759720X221140846.